India Seeks Partners With Pharmas, Hospitals To Make HIV Drugs
This article was originally published in PharmAsia News
Indian health authorities are requesting public-sector drug makers to manufacture low-cost drugs against HIV. The government has plans to join with major pharmaceutical companies and hospitals to develop other vital drugs at affordable prices. Indian drug makers already have offered to cooperate with the government, but have expressed a desire for a public-private partnership to develop the drugs. The proposed link with the private sector and hospitals would expand the HIV effort to include anti-cancer and other drugs for life-threatening diseases, but which are considered too expensive since they are to be taken over a long term. (Click here for more
You may also be interested in...
FRANKFURT, Germany - Indian Drugs and Pharmaceuticals Ltd., one of India's oldest government-owned units, is shedding its staid image and extending expertise and facilities to other drug companies through potential collaborations or joint ventures. Established in 1961, IDPL was formed with a socialistic outlook of fulfilling medical needs for the poor population in India
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.